GlassScriptPhysician profile
Ravinder K Agarwal
NPI 1477538007
$1,892.69
in general payments reported to CMS, 2019-2025
20 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $60.19 · 2021: $531 · 2022: $323 · 2023: $205 · 2024: $288 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.39 |
| Education | $157.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $497.26 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $251.86 | 2021-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $216.67 | 2021-2024 | Hyqvia, Cuvitru |
| Sanofi-Aventis U.S. LLC | $157.43 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $115.22 | 2023-2025 | |
| Genzyme Corporation | $100.62 | 2022-2025 | |
| Csl Behring | $85.41 | 2020-2024 | Hizentra |
| Pharming Healthcare, INC. | $83.74 | 2021-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $72.70 | 2021-2022 | |
| Insmed, INC. | $67.52 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $36.16 | 2021 | |
| Alk-Abello, INC | $32.38 | 2021-2025 | Timothy, Standardized, Standardized Mite D. Farinae, Histamine Positive |
| Regeneron Healthcare Solutions, INC. | $29.32 | 2025 | Dupixent |
| Genentech USA, INC. | $29.32 | 2025 | Xolair |
| Bio Products Laboratory USA, INC. | $23.59 | 2023 | Gammaplex, Coagadex |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $22.70 | 2022 | |
| Amgen INC. | $21.54 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $17.21 | 2025 | Neffy |
| Greer Laboratories, INC. | $16.43 | 2024 | Palforzia |
| Pfizer INC. | $15.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravinder Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.